ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / GH / insiders
DGX (78) LH (73) CNC (63) ILMN (77) ⌘ Pro Terminal β†’

Guardant Health Inc. (GH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$178.80 -3.51% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $177.33

Guardant Health Inc. (GH) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY) β†’
ROARABLE D+ β€’ SELL / AVOID Cap $24.87B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GH Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is GH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Guardant Health Inc. (NASDAQ: GH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $178.80 (-3.51% 1D, market cap $24.87B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GH ranks #252 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does GH compare to DGX and LH in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), GH carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 64.5%, and ROIC of -17.4%. By comparison, DGX (Quest Diagnostics Incorporated) holds a B+ grade (78/100 RQD, P/E 28.1x, ROIC 10.3%, cap $27.83B) and LH (Labcorp Holdings Inc.) posts a B grade (73/100 RQD, P/E 34.0x, ROIC 8.3%, cap $29.86B). Among the 5-stock peer group, DGX leads on earnings multiple (28.1x) while ILMN leads on capital efficiency (18.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GH?
β–Ό

Per GH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576280), Guardant Health Inc. generated $982.0M in revenue (+32.9% YoY), -$416.3M in net income, and -$233.1M in free cash flow against $2.01B in total assets and $950.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $177.33 (-0.82%)🧬 Dilution Drag (+1.64% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY β€’ 50.6% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510053
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ Β· Rk D
Cash (9)Whales (18)SEC (11)Macro (9)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
$206 Bull$175 Base$136 Bear
πŸ“¬ FREE GH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for GH)Realized 20D OHLCV Swing Band: Β±10%
Deterministic 5-Pillar Attribution (53/100 Composite)
πŸ” WHY GH SCORES 53/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+18/20 pts (34% of score)

20D Institutional Volume Accumulation (Β±10% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (21% of score)

Altman Z-Score 5.44 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 6/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
45
Grade D$162.09+0.3% Next Q
Q2 (-2Q)
48
Grade D$162.59+9.5% Next Q
Q3 (-1Q)
50
Grade C-$178.06+0.4% Next Q
Current
53
Grade D+$178.80-0.9% Hist 90D Ξ±
Trajectory: D (45) β†’ D+ (53)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a GH Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While GH currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($170.45) and Max Pain ($187.74) forces dealer call-delta covering toward $206.24.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GHβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œGH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

GH Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (GH)

No recent open-market Form 4 cluster sales or emergency dumps flagged on GH. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GH)

  • βœ“Walkthrough of GH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
GH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +96.12%πŸ“ HORIZONTAL RANGE
2026-11-02O $182.6H $185.3L $178.8C $178.8VOL 1.25M
RES: $203.8SUP: $155.0SMA50: $170.5SMA200: $131.2
$198.6$167.5$136.3$105.2$74.14RES $203.8SUP $155.0$178.82026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ GH Butterfly Map β†’ + Track GH β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
12.4%/yr Implied 5Y Growth

vs. +32.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GH today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for GH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GH)

Health Care Rank #252 of 1016 βš”οΈ DGX vs GH Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (GH vs. DGX, LH, CNC, ILMN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Guardant Health Inc. (GH) ranks #252 by composite RQD confidence (53/100, grade D+) and #64 by equity capitalization ($24.87B). Within this direct 5-issuer industry benchmark cohort, DGX leads on earnings valuation at 28.1x trailing P/E, while ILMN leads on capital efficiency and profitability with 18.2% ROIC and 66.1% gross margin. DGX currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with GH at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GH ACTIVE
Guardant Health Inc.
D+ 53/100 β€” 64.5% -17.4% -3.51% $24.87B Benchmark Subject
DGX
Quest Diagnostics Incorporated
B+ 78/100 28.1x 33.2% 10.3% -0.43% $27.83B /dgx-vs-gh β†’
LH
Labcorp Holdings Inc.
B 73/100 34.0x 28.8% 8.3% -1.84% $29.86B /lh-vs-gh β†’
CNC
Centene Corporation
C 63/100 β€” 8.1% -31.0% -0.25% $33.97B /cnc-vs-gh β†’
ILMN
Illumina Inc.
B+ 77/100 51.5x 66.1% 18.2% -18.64% $43.80B /ilmn-vs-gh β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001576280

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Guardant Health Inc. (GH) reported GAAP revenue of $982.0M (+32.9% vs. FY2024 revenue of $739.0M , and +74.1% cumulative change since FY2023) , GAAP net income of -$416.3M, operating cash flow of -$184.8M, and free cash flow of -$233.1M (+15.2% YoY). On the balance sheet, GH closed FY2025 with $2.01B in total assets against $950.8M in total debt (Altman Z-Score: 5.44, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $982.0M -$416.3M -$184.8M -$233.1M $2.01B $950.8M
FY2024 (FY) 2024-12-31 $739.0M -$436.4M -$239.9M -$274.9M $1.49B $731.4M
FY2023 (FY) 2023-12-31 $563.9M -$479.4M -$325.0M -$350.4M $13.68B $3.20B

3. GH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Guardant Health Inc. (NASDAQ: GH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $178.80 (-3.51% 1D, market cap $24.87B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GH ranks #252 in composite RQD confidence.

How does GH compare to DGX and LH in the Health Care sector?

Within the Health Care sector (Medical Specialities), GH carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 64.5%, and ROIC of -17.4%. By comparison, DGX (Quest Diagnostics Incorporated) holds a B+ grade (78/100 RQD, P/E 28.1x, ROIC 10.3%, cap $27.83B) and LH (Labcorp Holdings Inc.) posts a B grade (73/100 RQD, P/E 34.0x, ROIC 8.3%, cap $29.86B). Among the 5-stock peer group, DGX leads on earnings multiple (28.1x) while ILMN leads on capital efficiency (18.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GH?

Per GH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576280), Guardant Health Inc. generated $982.0M in revenue (+32.9% YoY), -$416.3M in net income, and -$233.1M in free cash flow against $2.01B in total assets and $950.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GH trading relative to its 50-day, 200-day, and 52-week technical levels?

GH last traded at $178.80 (-3.51% on volume of 1,502,593 shares), positioning the stock +4.90% above its 50-day simple moving average ($170.45) and +36.25% above its 200-day simple moving average ($131.23). Across its 52-week range of $74.55 to $191.05, GH sits at the 89.5% percentile with a 14-day RSI of 62.0 (BULLISH MOMENTUM) and an implied next-earnings move of Β±10.0% ($160.92 to $196.68).

GH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are GH insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies GH leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: GH RQD Cockpit GH 12M Forecast GH Earnings & Move GH Dividends & DRIP GH Insiders & 13F GH Whale Options GH Profit Sankey GH News & Why
ROARABLE RATING BRIEF β€’ RQD 53/100 (D+) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

GH β€” Guardant Health Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:12:56Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GH scores 53 out of 100 with a letter grade of D+, labeled "Roarable Sell β€” Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 9/20 (ROIC -17.4%; FCF yield -0.94%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 6/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 0.87; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 5.44; Piotroski F 6/9; Debt/Equity 0.85). The score is therefore carried mainly by institutional positioning, while the cash-generation and insider pillars are weak. For a prospective investor, the upside driver cited in the data is the institutional flow pillar; the principal valuation tradeoff is that the cash-engine pillar is weak against a forward P/E of 19 and a price of 185.31 near the top of its 52-week range. The forensic pillar indicates a balance sheet the source data characterizes as moderately leveraged with a passing Piotroski profile, but this does not offset negative operating economics. This brief is analytical and educational, not personalized financial advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$982.0M$-437.2M$-416.3MN/A$-233.1M$378.2M$950.8M
FY 2024$739.0M$-443.6M$-436.4MN/A$-274.9M$525.5M$731.4M
FY 2023$563.9M$-564.7M$-479.4MN/A$-350.4MN/A$3200.5M

Per the SEC financials, revenue rose from $563.9M (FY 2023) to $982.0M (FY 2025) while operating losses persisted in each period. Market data reports a gross margin of 64.5%, an operating margin of -44.5%, and a net margin of -42.4%. ROIC is -17.4% and FCF yield is -0.94%. Per the Roarable RQD rating forensic pillar, the Altman Z-Score is 5.44 and the Piotroski F-Score is 6/9, with a Debt/Equity ratio of 0.85.

Recent Catalysts & News Wire Analysis

  • Market wire (Yahoo! Finance Canada, Yahoo Finance Singapore): general market-action and institutional-positioning coverage; no specific event described in the summary text.
  • Price action (TradingKey): a report headlined an 8.27% decline on Oct 6 with no further detail in the summary.
  • Analyst commentary (Seeking Alpha, tagged CATALYST): headline states "Growth Remains Too Expensive, Reiterate Hold."
  • Technical commentary (FXEmpire): headline references a breakout with an upside price path toward $250; summary is generic.
  • Clinical/partnership item (Stock Titan): headline describes a blood test in Europe that may help identify patients who may benefit from AstraZeneca's breast cancer drug.

Risk watch items: the Seeking Alpha valuation headline and the reported October decline. Proprietary signals: none listed in the Butterfly Supply-Chain Graph. Per the Butterfly Supply-Chain Graph, supply chain is NONE with no butterfly links.

Open Questions

  • What is the P/E (TTM) and EV/EBITDA, given that both are reported as not available in source data while forward P/E is 19?
  • What specific drivers account for the FY 2023 debt of $3200.5M falling to $950.8M by FY 2025, and what is the company's debt maturity profile?
  • What is the path to positive operating income given reported operating margin of -44.5%?
  • Who are the institutional holders and insiders behind the Whale and Insider pillar scores, since the holders section is empty?
  • What is the EPS for FY 2025, since the financials list EPS as N/A across all periods?

GH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Guardant Health Inc. (GH) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to GH Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GH Bull vs. Bear Conversation Board β€” What's Your Call at $178.80?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GH 🐻 50% BEARISH CONVICTION
1. Pick Your Side on GH:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $200.13 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is GH (D+ β€’ RQD 53/100) a Buy at $185.31?

Welcome to the GH (Guardant Health Inc.) Roar Pit. Current RQD Composite is 53/100 (Roarable Sell β€” Weak Fundamentals / Trim) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $142.69 (-23.0%)
Spot @ $185.31

Pump the brakes on GH β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GH, but look at what you are paying: current EV/EBITDA multiples with 64.5% gross margins. Unless Guardant Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $233.49 (+26.0%)
Spot @ $185.31

GH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GH, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $185.31 (52-wk range $74.55 - $191.05), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%